Refine by
Leukemia Articles & Analysis: This-Year
6 articles found
This is crucial for biologics like L-asparaginase (Oncaspar®), where PEGylation reduces hypersensitivity reactions in leukemia patients. 3. Improved Stability and Solubility PEG's hydrophilic nature enhances drug solubility, particularly for poorly water-soluble compounds. ...
A major breakthrough occurred with the FDA approval of Venetoclax (ABT-199), a BCL2-selective inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Venetoclax works by mimicking BH3-only proteins, thereby displacing pro-survival BCL2 proteins and triggering apoptosis in cancer cells. In 2020, a study published in the New England Journal of Medicine demonstrated ...
This immunotherapy has shown remarkable success, particularly in hematologic malignancies such as acute lymphoblastic leukemia and certain types of lymphoma. However, the complexity and high costs associated with CAR-T development have prompted researchers and companies to seek more efficient and effective approaches. ...
It allows for the simultaneous detection of gene rearrangements and the expression of corresponding proteins, helping in the characterization of specific subtypes of leukemia and lymphoma. Furthermore, it sheds light on the interplay between genetic abnormalities and protein expression, offering insights into potential therapeutic targets. ...
Certain researchers joined hematopoietic stem cells (HSC) with platelets modified with anti-PD-1 antibodies (aPD-1) and delivered them back into mice with leukemia through intravenous injection. The HSC-platelet-aPD-1 conjugate reached the bone marrow to release aPD-1 locally which boosted the anti-leukemia immune response by increasing active T cells and ...
Immunotherapy in Leukemia Treatment Immunotherapy represents a paradigm shift in the treatment of leukemia. ...